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Background: Breast cancer is the second leading cause of cancer-related death among females in the world. To date, chemotherapy 
has been the most frequently used treatment for breast cancer and other cancers. However, some natural products have been used, as 
alternative treatments for cancers including breast cancer, due to their wide range of biological activities and low toxicity in animal 
models.
Objectives: The present study examined the anti-proliferative activity of curcumin and its effect(s) on the apoptosis of breast cancer cells.
Materials and Methods: This study was performed by an in vitro assay and the anticancer effects of curcumin were determined by MTT 
(3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide). We used quantitative real time Polymerase Chain Reaction (PCR) for 
detection of Mcl-1 gene expression in treated groups and then compared them to control samples.
Results: In the treatment group, there were higher levels of cell death changes than the control group. The results also showed that the 
Mcl-1 gene expression declined in the tested group as compared to the control group.
Conclusions: Our present findings indicated that curcumin significantly inhibited the growth of human breast cancer cell MCF-7 by 
inducing apoptosis in a dose- and time- dependent manner, accompanied by a decrease in MCF-7 cell viability. Furthermore, our results 
showed that quantitative real-time PCR could be used as a direct method for detection Mcl-1 gene expression in tested samples and normal 
samples.
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1. Background
It is known that breast cancer is the most common 
cancer for women worldwide, and accounts for approxi-
mately 25% of all female malignancies with a higher prev-
alence in developed countries. Breast cancer is the second 
leading cause of cancer-related death among females in 
the world (1). The discovery of novel natural compounds 
with low toxicity and high selectivity for killing cancer 
cells is an important area in cancer research (2).
To date, chemotherapy has been the most frequently 
used treatment for breast cancer and other cancers. 
However, this method of treatment also destroys some 
normal cells as well. Due to their wide range of biological 
activities and low toxicity in animal models, some natu-
ral products have been used as alternative treatments for 
cancers including breast cancer (2).
Curcumin or diferuloylmethane is the major yellow 
pigment extracted from turmeric (Curcuma longa) and is 
commonly used as a flavoring agent in food (3).
Curcumin has been widely studied for its anti-inflam-
matory, anti-angiogenic, antioxidant, wound healing, 
and anti-cancer effects because of its medicinal proper-
ties in Indian and Chinese medicine (2). Moreover, exten-
sive research has shown that curcumin possesses anti-
proliferative and anti-carcinogenic properties in a wide 
variety of cell lines and animals (4).
In addition, recent studies have shown that curcumin, 
either alone or in combination with other anticancer 
agents, can efficiently induce apoptosis (2).
Apoptosis is a tightly regulated process of programmed 
cell death, including the activation of various molecules 
for initiating cell death.
Specific activation of apoptosis in tumor cells offers a 
promising approach for cancer therapy. However, the 
specific mechanisms of curcumin-induced cytotoxicity 
remain controversial due to the variable anti-and pro-
apoptotic signaling pathways in different cell types.
Oxidative stress derived from curcumin through pro-
duction of reactive oxygen species and oxidative dam-
age causes DNA modification. This process continues 
and carries on proteolytic events and induces apoptosis 
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(4). Plenty of proteins and a number of genes regulate 
apoptosis, in which two pairs of proteins play an impor-
tant part. Bcl-2 is a member of a family of proteins in-
volved both in preventing apoptosis (pro-survival) and 
in promoting it (pro-apoptotic). Anti-apoptotic proteins 
include the Bcl-2 family (such as Bcl-2, Bcl-XL, Mcl-1 etc.). 
Pro-apoptotic proteins are sub-grouped into the Bax fam-
ily (such as Bax, Bak, etc.) and the BH3-only family (such as 
Bid, Bad, Bim, etc.) (5).
The Tumor Necrosis Factor (TNF)-Related Apoptosis In-
ducing Ligand (TRAIL) has promising anticancer activity. 
Curcumin enhances TRAIL-induced apoptosis of breast 
cancer cells by regulating apoptosis-related proteins 
(such as Mcl-1, ERK and Akt) (6, 7).
2. Objectives
The exact mechanism by which curcumin exerts its 
apoptotic effects in breast cancer cells still remains un-
clear. The present study examined the anti-proliferative 
activity of curcumin on breast cancer cells.
3. Materials and Methods
3.1. Reagents
Curcumin was purchased from Sigma-Aldrich Corpora-
tion and was prepared with Dimethyl Sulfoxide (DMSO) 
at a concentration of 10 mM, stored as small aliquots at 
-20°C, and thawed and diluted as needed in cell culture 
medium. Dimethyl Sulfoxide, Propidium Iodide (PI) and 
trypsin were purchased from sigma (St, Louis, Mo, USA). 
Roswell Park Memorial Institute (RPMI) 1640, penicillin, 
streptomycin and other cell culture supplies were from 
Gibco BRL (Grand Island, NT, USA). Fetal bovine serum 
was from Hyclone (Logan, UT, USA). MTT (3-(4,5-dimeth-
ylthiazol-2-yl)- 2,5- diphenyl trazolium bromide) was ob-
tained from Fluka (Ron Konkoma, NY, USA).
3.2. Cell Line and Culture
Human breast cancer cell line, MCF7, was obtained from 
the Pasteur institute of Iran. These cells were cultivated 
in T75 tissue culture flasks in RPMI-1640 supplemented 
with 10% fetal calf serum, 100 μg/mL penicillin, 100 μg/mL 
streptomycin, 2 mM L-glutamine, and 20 mM hydroxy-
ethyl piperazine ethanesulfonic acid, and incubated in a 
humidified incubator containing 5% CO2 at 37°C.3.3. MTT Assay
Cell viability was assessed using the MTT assay. Breast 
cancer (5 × 103) cells were seeded in 200 μL of RPMI-1640 
medium in 96-well plates, and cultured overnight. Next, 
the medium was replaced with fresh RPMI-1640 or the 
same media containing different concentrations of cur-
cumin. After a further incubation for 24 or 48 hours, 50 
μL of MTT (2 mg/mL) was added to each well followed by 
4 hours of incubation. The medium was discarded and 
150 μL of dimethyl sulfoxide was added to each well, and 
incubated for 20 minutes. The OD was measured at 490 
nm. The cell viability index was calculated according to 
the following Equations:
(1)
Cytotoxicity% =1 − Mean absorbance of toxicantMean absorbance of negative control ×100
(2)
Viability%= 100−Cytotoxicity%
To diminish test error level, the MTT strain was added 
to wells without cells and along with other wells, absor-
bance level was read and ultimately subtracted from the 
entire absorbance.3.4. Real-Time Polymerase Chain Reaction with SYBR Green I
Total RNA was extracted from cells using an RNA isola-
tion reagent (sigma) as recommended by the manufac-
turer and the extracted RNA was purified using RNeasy 
Mini Kit (Qiagen), and cDNA was synthesized using Quan-
titect Reverse Transcription Kit (Qiagen) according to the 
manufacturer’s instructions. Reverse transcription was 
carried out as follows: 42°C for two minutes, 42°C for 15 
minutes, and 95°C for three minutes (one cycle). cDNA 
was stored at -20°C for PCR.
Real-time PCR was performed in a 25 μL reaction solution. 
The following sequences were used as primers (Table 1).
Real time PCR was carried out in optical grade 96-well 
plates (Micro amp, Applied Biosystems, Singapore) at re-
action volume of 25 μL, including 12.5 SYBR Green Master 
Mix (Primer design), 300 nm of each primer and 5 ng of 
template DNA. All samples were run in duplicates. Ther-
mal cycling was performed on the Applied Biosystems 
7300 real-time PCR system. Threshold cycle (Ct) data were 
collected using ABI Prism 7300 sequence detection sys-
tem version 1.2.3 (Applied Biosystems, UK).
The relative gene expression was analyzed by the 2- ΔΔCt 
method. The fold change in target gene cDNA relative to 
the HPRT (Hypoxanthine-guanine phosphoribosyltrans-
ferase) internal control was determined by:
Fold change= 2- ΔΔCt
Where ΔΔCt = (Ct Mcl-1- Ct HPRT)-(Ct Mcl-1-Ct HPRT)
Table 1. Characteristics of the Primers Used in the Real-Time 
Polymerase Chain Reaction
Gene Sequence
Mcl-1(F) GTGCCTTTGTGGCTAAACACT
Mcl-1® AGTCCCGTTTTGTCCTTACGA
3.5. Statistical Analysis
Statistical significances were calculated using the Stu-
dent’s t-test and one-way analysis of variance.
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4. Results
4.1. The Effects of Curcumin on Inhibition and Pro-liferation of MCF7 Cell Line 
The effect of curcumin was studied as a dose-response 
experiment. Proliferation of MCF7 cells was significantly 
inhibited by curcumin in a concentration-dependent 
manner during 48 hours (P < 0.01). Different concentra-
tions of curcumin at 48 hours had different cytotoxicity 
effects on MCF7 cell line (Figure 1).
The 50% inhibition concentration (IC50) values of cur-
cumin on MCF7 cells was determined (Figure 2). Further-
more, IC50 was determined by probit analysis using the 
Pharm PCS (Pharmacologic Calculation System) statisti-
cal package (Springer-Verlag, USA). There were significant 
differences in IC50 curcumin (P < 0.05).
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Figure 3. Melting Curve Analysis of the Mcl-1 and HPRT Genes
As expected, there was a significant difference between 
the tested and normal samples regarding Mcl-1 gene ex-
pression changes. To optimize and validate the real-time 
PCR assay before using the ΔΔCT method for gene expres-
sion, a validation experiment was performed to deter-
mine the PCR efficiencies of the target and the reference 
genes. Melting curve analysis was performed for every 
single reaction to exclude amplification of non-specific 
products. Each valid amplification reaction displayed a 
single peak at the expected Tm (melting temperature). 
The results also showed that Mcl-1 gene expression de-
clined in the control group as compared to the experi-
mental group. The mean ratio was determined for both 
groups as follows: 1.04 ± 0.13 for control group, and 0.49 ± 
0.12 for the experimental group.
5. Discussion
For centuries, curcumin has been consumed in the 
diet and used as a herbal medicine in several Far Eastern 
Countries (2). Curcumin has cancer chemopreventive 
properties in a variety of animal models of chemical car-
cinogenesis, including those resulting in tumors of the 
mammary gland (6, 7).
Oxidative stress and oxidative damage are involved in 
the pathophysiology of many chronic inflammatory and 
degenerative disorders, particularly cancer. The genera-
tion of Reactive Oxygen Species (ROS), particularly O2− 
and OH, play important roles in the development of can-
cer (8, 9). Curcumin has been shown to scavenge O2− and 
OH radicals (10, 11).
As evident curcumin expresses anti-oxidant, anti-in-
flammatory, anti-antigenic, anti-mitotic and anti-meta-
static activities in vitro and in animal experiments, thus 
it might be a promising molecule for the prevention and 
treatment of cancer in humans. Curcumin has antiprolif-
erative effects in different types of cell lines in vitro. One 
of the initial reported descriptions of curcumin cyto-
toxicity occurred in Dalton’s lymphoma ascites cells, in 
which curcumin at a concentration of 4 μg/mL produced 
50% cytotoxicity. Curcumin also inhibited the growth of 
Chinese hamster ovary cells and human leukemic lym-
phocytes in culture (12). At a concentration of 20 μg/mL, 
curcumin produced 50% growth arrest in K-562 human 
chronic myelogenous leukemia cells (13).
Curcumin has also been shown to inhibit the growth 
of human breast cancer cell lines in vitro (5), including 
HL60, k562, MCF- 7 and Hela cells (14). Also, to date, no 
curcumin-related toxicity was observed in either ex-
perimental animals or humans, even at very high doses 
(15). Our data are consistent with previous studies that 
reported curcumin exerts its anticancer effects via pro-
liferation inhibition and apoptosis induction in breast 
cancer cells (15). In this study, the effect of different cur-
cumin doses (0 - 100 μm) on MCF-7 cell morphology was 
examined. After a 24-hour period, curcumin treatment 
caused MCF-7 cell shrinkage, rounding and partial de-
tachment, thus demonstrating the cytotoxic effects of 
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curcumin on MCF-7 cells. On assaying the effect of cur-
cumin on cell viability by the MTT assay, we observed a 
decrease in cell viability. At curcumin concentration of 
40 μm, significant loss of viability can be detected during 
the 0-24 hour treatment period.
It is important to mention that curcumin-mediated 
reduction of cell viability was dose- and time- depen-
dent. Our present findings indicate that curcumin sig-
nificantly inhibited the growth of human breast cancer 
cell MCF-7 by inducing apoptosis in a dose- and time- 
dependent manner, accompanied by a decrease in MCF-
7 cell viability.
Curcumin is highly cytotoxic toward several colon can-
cer cell lines. Curcumin blocked the entry to cell cycle 
from G2 to M by inhibiting expression of cdc2/cyclin B 
(16). The proapoptotic members of the Bcl-2 family, such 
as Bax, were activated, and antiapoptotic genes such as 
Bcl-XL were inhibited by curcumin (17).
Curcumin also triggers caspase-3-mediated cell death. It 
activated GADD153, which in turn acts as an activator of 
apoptosis (18). Curcumin decreases the expression of an-
tiapoptotic members of the Bcl-2 family and elevates the 
expression of p53, Bax, and procaspases-3, -8 and -9 (19). 
We selected the Mcl-1 gene, because the bcl-2 family of 
proteins functions as pro- and anti-apoptotic members 
(20). The bcl-2 members such as bax, bak, bad or bcl-Xs 
promote apoptosis, whereas other members such as bcl-
2 and bcl-Xl prevent apoptosis by blocking the transloca-
tion of cytochrome c, and subsequent caspase activation. 
Mitochondria are involved in excitotoxic injury during 
cerebral ischemia and the release of cytochrome C, an 
apoptogenic factor that propagates death signals by trig-
gering caspases leading to cell death. Using these assay, 
status of all subjects was successfully determined (5). We 
expanded the coverage of the detectable Mcl-1 gene by 
SYBR Green assay for Mcl-1 gene expression. 
Given the potential and safety of curcumin, it is a prom-
ising candidate for therapy of breast cancer, although ad-
ditional studies are needed.
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